Cargando…

Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients

SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction that emerges weeks after the acute respiratory infection. To better understand this pathology, we prospectively analyzed of a cohort of cancer patients with neurologic manifestations of COVID-19, including a targeted proteomics a...

Descripción completa

Detalles Bibliográficos
Autores principales: Remsik, Jan, Wilcox, Jessica A., Babady, N. Esther, McMillen, Tracy A., Vachha, Behroze A., Halpern, Neil A., Dhawan, Vikram, Rosenblum, Marc, Iacobuzio-Donahue, Christine A., Avila, Edward K., Santomasso, Bianca, Boire, Adrienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833316/
https://www.ncbi.nlm.nih.gov/pubmed/33508216
http://dx.doi.org/10.1016/j.ccell.2021.01.007
_version_ 1783642037421080576
author Remsik, Jan
Wilcox, Jessica A.
Babady, N. Esther
McMillen, Tracy A.
Vachha, Behroze A.
Halpern, Neil A.
Dhawan, Vikram
Rosenblum, Marc
Iacobuzio-Donahue, Christine A.
Avila, Edward K.
Santomasso, Bianca
Boire, Adrienne
author_facet Remsik, Jan
Wilcox, Jessica A.
Babady, N. Esther
McMillen, Tracy A.
Vachha, Behroze A.
Halpern, Neil A.
Dhawan, Vikram
Rosenblum, Marc
Iacobuzio-Donahue, Christine A.
Avila, Edward K.
Santomasso, Bianca
Boire, Adrienne
author_sort Remsik, Jan
collection PubMed
description SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction that emerges weeks after the acute respiratory infection. To better understand this pathology, we prospectively analyzed of a cohort of cancer patients with neurologic manifestations of COVID-19, including a targeted proteomics analysis of the cerebrospinal fluid. We find that cancer patients with neurologic sequelae of COVID-19 harbor leptomeningeal inflammatory cytokines in the absence of viral neuroinvasion. The majority of these inflammatory mediators are driven by type II interferon and are known to induce neuronal injury in other disease states. In these patients, levels of matrix metalloproteinase-10 within the spinal fluid correlate with the degree of neurologic dysfunction. Furthermore, this neuroinflammatory process persists weeks after convalescence from acute respiratory infection. These prolonged neurologic sequelae following systemic cytokine release syndrome lead to long-term neurocognitive dysfunction. Our findings suggest a role for anti-inflammatory treatment(s) in the management of neurologic complications of COVID-19 infection.
format Online
Article
Text
id pubmed-7833316
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-78333162021-01-26 Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients Remsik, Jan Wilcox, Jessica A. Babady, N. Esther McMillen, Tracy A. Vachha, Behroze A. Halpern, Neil A. Dhawan, Vikram Rosenblum, Marc Iacobuzio-Donahue, Christine A. Avila, Edward K. Santomasso, Bianca Boire, Adrienne Cancer Cell Article SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction that emerges weeks after the acute respiratory infection. To better understand this pathology, we prospectively analyzed of a cohort of cancer patients with neurologic manifestations of COVID-19, including a targeted proteomics analysis of the cerebrospinal fluid. We find that cancer patients with neurologic sequelae of COVID-19 harbor leptomeningeal inflammatory cytokines in the absence of viral neuroinvasion. The majority of these inflammatory mediators are driven by type II interferon and are known to induce neuronal injury in other disease states. In these patients, levels of matrix metalloproteinase-10 within the spinal fluid correlate with the degree of neurologic dysfunction. Furthermore, this neuroinflammatory process persists weeks after convalescence from acute respiratory infection. These prolonged neurologic sequelae following systemic cytokine release syndrome lead to long-term neurocognitive dysfunction. Our findings suggest a role for anti-inflammatory treatment(s) in the management of neurologic complications of COVID-19 infection. Elsevier Inc. 2021-02-08 2021-01-16 /pmc/articles/PMC7833316/ /pubmed/33508216 http://dx.doi.org/10.1016/j.ccell.2021.01.007 Text en © 2021 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Remsik, Jan
Wilcox, Jessica A.
Babady, N. Esther
McMillen, Tracy A.
Vachha, Behroze A.
Halpern, Neil A.
Dhawan, Vikram
Rosenblum, Marc
Iacobuzio-Donahue, Christine A.
Avila, Edward K.
Santomasso, Bianca
Boire, Adrienne
Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients
title Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients
title_full Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients
title_fullStr Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients
title_full_unstemmed Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients
title_short Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients
title_sort inflammatory leptomeningeal cytokines mediate covid-19 neurologic symptoms in cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833316/
https://www.ncbi.nlm.nih.gov/pubmed/33508216
http://dx.doi.org/10.1016/j.ccell.2021.01.007
work_keys_str_mv AT remsikjan inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT wilcoxjessicaa inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT babadynesther inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT mcmillentracya inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT vachhabehrozea inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT halpernneila inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT dhawanvikram inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT rosenblummarc inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT iacobuziodonahuechristinea inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT avilaedwardk inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT santomassobianca inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients
AT boireadrienne inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients